Adam Schayowitz - 09 Apr 2026 Form 3 Insider Report for Zymeworks Inc. (ZYME)

Reporting relationship: Exhibit List - Exhibit 24 - Power of Attorney EVP, Head of Research & Development
Issuer ticker: ZYME
Reported as of: 09 Apr 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 10 Apr 2026, 16:05:08 UTC
Source filing: View source filing
Reporting owner signature: /s/ Catherine Graham, Attorney-in-Fact

Key filing fact

Adam Schayowitz filed Form 3 for Zymeworks Inc. (ZYME) on 10 Apr 2026.

Key facts

This page summarizes Adam Schayowitz's Form 3 filing for Zymeworks Inc. (ZYME).
0 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Apr 2026, 16:05.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127119 Primary reporting owner

Schayowitz Adam

Relationship: Exhibit List - Exhibit 24 - Power of Attorney EVP, Head of Research & Development
Address: C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Signature: /s/ Catherine Graham, Attorney-in-Fact
Signature date: 10 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZYME holding

No securities are beneficially owned

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 09 Apr 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 167,000
Exercise price: $16.92
Footnotes: F1, F2

ZYME holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 111,111
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Stock option granted October 9, 2025.

Footnote F2

Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.

Footnote F3

Restricted stock units ("RSUs") granted October 9, 2025; vest in three equal annual installments beginning October 9, 2026.

Footnote F4

Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.

SEC remarks

Exhibit List - Exhibit 24 - Power of Attorney EVP, Head of Research & Development